Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Searching for a Common Thrombo-Inflammatory Basis in Patients With Deep Vein Thrombosis or Peripheral Artery Disease.

Kremers BMM, Birocchi S, van Oerle R, Zeerleder S, Spronk HMH, Mees BME, Luken BM, Ten Cate H, Ten Cate-Hoek AJ.

Front Cardiovasc Med. 2019 Apr 2;6:33. doi: 10.3389/fcvm.2019.00033. eCollection 2019.

2.

Mouse venous thrombosis upon silencing of anticoagulants depends on tissue factor and platelets, not FXII or neutrophils.

Heestermans M, Salloum-Asfar S, Streef T, Laghmani EH, Salvatori D, Luken BM, Zeerleder SS, Spronk HMH, Korporaal SJ, Kirchhofer D, Wagenaar GTM, Versteeg HH, Reitsma PH, Renné T, van Vlijmen BJM.

Blood. 2019 May 9;133(19):2090-2099. doi: 10.1182/blood-2018-06-853762. Epub 2019 Mar 21.

PMID:
30898865
3.

The damage-associated molecular pattern HMGB1 is released early after clinical hepatic ischemia/reperfusion.

van Golen RF, Reiniers MJ, Marsman G, Alles LK, van Rooyen DM, Petri B, Van der Mark VA, van Beek AA, Meijer B, Maas MA, Zeerleder S, Verheij J, Farrell GC, Luken BM, Teoh NC, van Gulik TM, Murphy MP, Heger M.

Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1192-1200. doi: 10.1016/j.bbadis.2019.01.014. Epub 2019 Jan 15.

PMID:
30658161
4.

Autoregulation of von Willebrand factor function by a disulfide bond switch.

Butera D, Passam F, Ju L, Cook KM, Woon H, Aponte-Santamaría C, Gardiner E, Davis AK, Murphy DA, Bronowska A, Luken BM, Baldauf C, Jackson S, Andrews R, Gräter F, Hogg PJ.

Sci Adv. 2018 Feb 28;4(2):eaaq1477. doi: 10.1126/sciadv.aaq1477. eCollection 2018 Feb.

5.

DNA and factor VII-activating protease protect against the cytotoxicity of histones.

Marsman G, von Richthofen H, Bulder I, Lupu F, Hazelzet J, Luken BM, Zeerleder S.

Blood Adv. 2017 Nov 30;1(26):2491-2502. doi: 10.1182/bloodadvances.2017010959. eCollection 2017 Dec 12.

6.

Inflammatory and endothelial markers during vaso-occlusive crisis and acute chest syndrome in sickle cell disease.

Schimmel M, Luken BM, Nur E, van Tuijn CFJ, Sins JW, Brandjes DPM, Zeerleder SS, Biemond BJ.

Am J Hematol. 2017 Nov;92(11):E634-E636. doi: 10.1002/ajh.24868. Epub 2017 Oct 3. No abstract available.

7.

Coagulation factor XI improves host defence during murine pneumonia-derived sepsis independent of factor XII activation.

Stroo I, Zeerleder S, Ding C, Luken BM, Roelofs JJTH, de Boer OJ, Meijers JCM, Castellino FJ, van 't Veer C, van der Poll T.

Thromb Haemost. 2017 Jul 26;117(8):1601-1614. doi: 10.1160/TH16-12-0920. Epub 2017 May 11.

PMID:
28492700
8.

Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.

Sins JWR, Schimmel M, Luken BM, Nur E, Zeerleder SS, van Tuijn CFJ, Brandjes DPM, Kopatz WF, Urbanus RT, Meijers JCM, Biemond BJ, Fijnvandraat K.

J Thromb Haemost. 2017 Jul;15(7):1392-1402. doi: 10.1111/jth.13728. Epub 2017 Jun 5.

9.

Extracellular histones, cell-free DNA, or nucleosomes: differences in immunostimulation.

Marsman G, Zeerleder S, Luken BM.

Cell Death Dis. 2016 Dec 8;7(12):e2518. doi: 10.1038/cddis.2016.410. Review.

10.

Role of platelets, neutrophils, and factor XII in spontaneous venous thrombosis in mice.

Heestermans M, Salloum-Asfar S, Salvatori D, Laghmani el H, Luken BM, Zeerleder SS, Spronk HM, Korporaal SJ, Wagenaar GT, Reitsma PH, van Vlijmen BJ.

Blood. 2016 May 26;127(21):2630-7. doi: 10.1182/blood-2015-10-672766. Epub 2016 Mar 1. Retraction in: Blood. 2018 Jun 28;131(26):2996.

11.

FSAP-mediated nucleosome release from late apoptotic cells is inhibited by autoantibodies present in SLE.

Marsman G, Stephan F, de Leeuw K, Bulder I, Ruinard JT, de Jong J, Westra J, Bultink IE, Voskuyl AE, Aarden LA, Luken BM, Kallenberg CG, Zeerleder S.

Eur J Immunol. 2016 Mar;46(3):762-71. doi: 10.1002/eji.201546010. Epub 2015 Dec 22.

12.

Conformational activation of ADAMTS13.

South K, Luken BM, Crawley JT, Phillips R, Thomas M, Collins RF, Deforche L, Vanhoorelbeke K, Lane DA.

Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18578-83. doi: 10.1073/pnas.1411979112. Epub 2014 Dec 15.

13.

Complexes of factor VII-activating protease with plasminogen activator inhibitor-1 in human sepsis.

Stephan F, Bulder I, Luken BM, Hazelzet J, Wuillemin WA, Zeerleder S.

Thromb Haemost. 2014 Jul 3;112(1):219-21. doi: 10.1160/TH13-12-1062. Epub 2014 Mar 20. No abstract available.

PMID:
24651925
14.

Control of VWF A2 domain stability and ADAMTS13 access to the scissile bond of full-length VWF.

Lynch CJ, Lane DA, Luken BM.

Blood. 2014 Apr 17;123(16):2585-92. doi: 10.1182/blood-2013-11-538173. Epub 2014 Feb 20.

15.

High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women.

Andersson HM, Siegerink B, Luken BM, Crawley JT, Algra A, Lane DA, Rosendaal FR.

Blood. 2012 Feb 9;119(6):1555-60. doi: 10.1182/blood-2011-09-380618. Epub 2011 Nov 22.

16.

Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura.

Froehlich-Zahnd R, George JN, Vesely SK, Terrell DR, Aboulfatova K, Dong JF, Luken BM, Voorberg J, Budde U, Sulzer I, Lämmle B, Kremer Hovinga JA.

Haematologica. 2012 Feb;97(2):297-303. doi: 10.3324/haematol.2011.051433. Epub 2011 Oct 11.

17.

Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor.

Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA.

Blood. 2011 Sep 22;118(12):3212-21. doi: 10.1182/blood-2011-02-306597. Epub 2011 Jun 29. Review.

18.

Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura.

Pos W, Luken BM, Sorvillo N, Kremer Hovinga JA, Voorberg J.

J Thromb Haemost. 2011 Jul;9(7):1285-91. doi: 10.1111/j.1538-7836.2011.04307.x. Review.

19.

The importance of vicinal cysteines, C1669 and C1670, for von Willebrand factor A2 domain function.

Luken BM, Winn LY, Emsley J, Lane DA, Crawley JT.

Blood. 2010 Jun 10;115(23):4910-3. doi: 10.1182/blood-2009-12-257949. Epub 2010 Mar 30.

20.

Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1-like domain.

Andersson HM, Arantes MJ, Crawley JT, Luken BM, Tran S, Dahlbäck B, Lane DA, Rezende SM.

Blood. 2010 Jun 10;115(23):4878-85. doi: 10.1182/blood-2009-11-256610. Epub 2010 Mar 22.

21.

An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF.

Pos W, Crawley JT, Fijnheer R, Voorberg J, Lane DA, Luken BM.

Blood. 2010 Feb 25;115(8):1640-9. doi: 10.1182/blood-2009-06-229203. Epub 2009 Dec 23.

22.

Circulating ADAMTS-13-von Willebrand factor complexes: an enzyme on demand.

Crawley JT, de Groot R, Luken BM.

J Thromb Haemost. 2009 Dec;7(12):2085-7. doi: 10.1111/j.1538-7836.2009.03621.x. Epub 2009 Sep 18. No abstract available.

23.

VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.

Pos W, Luken BM, Kremer Hovinga JA, Turenhout EA, Scheiflinger F, Dong JF, Fijnheer R, Voorberg J.

J Thromb Haemost. 2009 Mar;7(3):421-8. doi: 10.1111/j.1538-7836.2008.03250.x.

24.

Extracellular control of VWF multimer size and thiol-disulfide exchange.

Luken BM.

J Thromb Haemost. 2008 Jul;6(7):1131-4. doi: 10.1111/j.1538-7836.2008.03031.x. Epub 2008 Jul 1. Review. No abstract available.

25.

Antibodies against the CUB1-2 domains of ADAMTS13 in a patient with benign monoclonal gammopathy: no causal relationship.

Riksen NP, Luken BM, Klasen IS, Voorberg J, Crama N, van Deuren M.

Haematologica. 2007 Jul;92(7):e74-6.

26.

Differential effects of the loss of intrachain- versus interchain-disulfide bonds in the cystine-knot domain of von Willebrand factor on the clinical phenotype of von Willebrand disease.

Tjernberg P, Vos HL, Spaargaren-van Riel CC, Luken BM, Voorberg J, Bertina RM, Eikenboom JC.

Thromb Haemost. 2006 Dec;96(6):717-24.

PMID:
17139364
27.

Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP.

Luken BM, Turenhout EA, Kaijen PH, Greuter MJ, Pos W, van Mourik JA, Fijnheer R, Voorberg J.

Thromb Haemost. 2006 Sep;96(3):295-301.

PMID:
16953270
28.

Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura.

Luken BM, Kaijen PH, Turenhout EA, Kremer Hovinga JA, van Mourik JA, Fijnheer R, Voorberg J.

J Thromb Haemost. 2006 Nov;4(11):2355-64. Epub 2006 Aug 8.

29.

The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura.

Luken BM, Turenhout EA, Hulstein JJ, Van Mourik JA, Fijnheer R, Voorberg J.

Thromb Haemost. 2005 Feb;93(2):267-74.

PMID:
15711742

Supplemental Content

Loading ...
Support Center